← Back to patent-cliff list
CAS 221342-49-0
Spiro[3.5]non-7-en-6-one
Codes: (VII)992511-1-a
Application context (from source-drug indications)
Chronic lymphocytic leukaemiaLisaftoclaxAcute promyelocytic leukaemiaLisaftoclaxMyelodysplastic syndromeLisaftoclaxAcute myeloid leukaemiaLisaftoclaxDiffuse large B-cell lymphomaLisaftoclaxSystemic lupus erythematosusLisaftoclax
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Lisaftoclax | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
Cyclobutanone→1-(Triphenylphosphoranylidene)-2-propanone→1-Cyclobutylidenepropan-2-one→Carbonic acid dimethyl diester→Spiro[3.5]nonane-6,8-dione→8-(2-Methylpropoxy)spiro[3.5]non-7-en-6-one→Spiro[3.5]non-7-en-6-one→Spiro[3.5]nonan-6-one→1,3-Dimethyl propanedioate→Methyl 6-oxospiro[3.5]nonane-7-carboxylate→Methyl 6-(((trifluoromethyl)sulfonyl)oxy) spiro[3.5]non-6-ene-7-carboxylate→(4-Chlorophenyl)boranediol→Methyl 6-(4-chlorophenyl)spiro[3.5]non-6-ene-7-carboxylate→[6-(4-Chlorophenyl)spiro[3.5]non-6-en-7-yl]methanol→7-(Chloromethyl)-6-(4-chlorophenyl)spiro[3.5]non-6-ene
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.